News | August 06, 2024
Cupid post Q1 FY25 profit at Rs. 8.25 Cr
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Shivani Satish Wagh takes on the role of Joint Managing Director
Subscribe To Our Newsletter & Stay Updated
